The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis

Journal of Infectious Diseases

Volumn 211, Issue 1, 2015, Pages 80-90

  Mair Jenkins, John ^a   Saavedra Campos, Maria ^c   Baillie, J Kenneth ^d   Cleary, Paul ^c   Khaw, Fu Meng ^a   Lim, Wei Shen ^b   Makki, Sophia ^a   Rooney, Kevin D ^e   Nguyen Van Tam, Jonathan S ^a   Beck, Charles R ^a   Mateus, Ana L P ^c   Reuter, Simone ^f   Shin, Jinho ^g   Xu, Xiaolin ^g   Pereyaslov, Dmitriy ^g   Papieva, Irina ^g   Tegnell, Anders ^h   Englund, Hélène ^h   Elfving, Asa ^h   Cox, Rebecca ^i,j   Greve IsdahlMohn, Kristin ^i,j   Jenkins, Yingjie Feng ^k   more..

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^f SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

^h SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

ⁱ UNIVERSITY OF BERGEN   (Norway)

^j HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^k NATIONAL HEALTH SERVICE   (United Kingdom)

more..

Author keywords

convalescent plasma; MERS coronavirus; meta analysis.; severe acute respiratory infection; systematic review

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; IMMUNOGLOBULIN;

ANTIBODY TITER; ARTICLE; CHILL; CLINICAL EFFECTIVENESS; CONVALESCENT PLASMA INFUSION; CORONAVIRUS INFECTION; EXTRACORPOREAL OXYGENATION; FEVER; HUMAN; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INTENSIVE CARE; LENGTH OF STAY; META ANALYSIS; MORTALITY; PLASMA TRANSFUSION; POST HOC ANALYSIS; SARS CORONAVIRUS; SARS CORONAVIRUS INFECTION; SEVERE ACUTE RESPIRATORY SYNDROME; SPANISH INFLUENZA; SWEAT; SYSTEMATIC REVIEW; VIRAL RESPIRATORY TRACT INFECTION; IMMUNOLOGY; INFLUENZA, HUMAN; PLASMA; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; RISK;

HUMANS; IMMUNOGLOBULINS; INFLUENZA, HUMAN; PLASMA; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS; RISK; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 84922440585     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu396     Document Type: Article

References (50)

1. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV)-update (26 May 2014). http://www.who.int/csr/don/2014-05-23-mers/en/. Accessed 26 May 2014.
2. World Health Organization. Clinical management of severe acute respiratory infections when novel coronavirus is suspected: what to do and what not to do. http://www.who.int/csr/disease/coronavirus-infections/InterimGuidance-ClinicalManagement-NovelCoronavirus-11Feb13u. pdf. Accessed 5 July 2014.
3. Public Health England, ISARIC. Treatment of MERS-CoV: decision support tool v.1.0. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317139281416. Accessed 18 October 2013.
4. The WHO MERS-CoV Research Group. State of knowledge and data gaps of middle east respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr Outbreaks 2013; pii: ecurrents.outbreaks.0bf 719e352e7478f8ad85fa30127ddb8.
5. Hung IFN, To KKW, Lee C-K, et al. Hyperimmune iv immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza a(H1N1) infection. Chest 2013; 144:464-73.
6. Lai ST. Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis 2005; 24:583-91.
7. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006; 3:e343.
8. Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005; 56:919-22.
9. Wong SS, Yuen KY. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother 2008; 62: 437-41.
10. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
11. Mair-Jenkins J, Saavedra-Campos M, Nguyen-Van-Tam J, Beck C. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and the effectiveness of convalescent plasma for the treatment of severe acute respiratory infections of viral aetiology: a systematic review. PROSPERO 2013CRD42013005091. http://www.crd.york.ac.uk/PROSPERO/display-record.asp?ID=CRD42013005091. Accessed 12 June 2013.
12. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Updated March 2011. Oxford, UK: The Cochrane Collaboration, 2011. http:www.cochrane-handbook.org. Accessed 12 June 2013.
13. Tugwell P, Wells G. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. http://www. ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed 20 June 2013.
14. West S, King V, Carey T, Lohr K, McKoy N, Sutton S. Systems to rate the strength of scientific evidence: summary. Rockville, MD: Agency for Health Research and Quality, 2002.
15. Centre for Reviews and Dissemination. Systematic Reviews: CRDs guidance for undertaking reviews in health care. York: University of York, 2009.
16. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One 2011; 6:e29249.
17. Bass J, Ervin CE. Use of serum in the treatment of influenza-pneumonia. Nav Med Bull 1919; 71-3.
18. Simici D. Treatment of influenza with injections of blood from convalescents. Paris Med J 1922; 43:474-7.
19. Jacobaeus. Treatment of influenza pneumonia with serum from convalescents. Sven Lakartidnin 1920; 18:385-99.
20. Redden W. Treatment of influenza pneumonia by use of convalescent human serum. Boston Med Surg J 1919; 161:688-91.
21. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
22. Ortiz JR, Rudd KE, Clark DV, Jacob ST, West TE. Clinical research during a public health emergency: a systematic review of severe pandemic influenza management. Crit Care Med 2013; 41:1345-52.
23. Kong LK. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J 2006; 12:489.
24. Wiesneth M, Harter G, Schulz A, Rauch S, Mertens T, Schrezenmeier H. Convalescent plasma for prophylaxis and treatment of severe pandemic influenza A (H1N1) 2009 infection: Case reports. Vox Sang 2010; 99:238.
25. Wong VWS, Dai D, Wu AKL, Sung JJY. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003; 9:199-201.
26. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357:1450-1.
27. Zhang HP, Zeng YM, Lin ZS, et al. Clinical characteristics and therapeutic experience of case of severe highly pathogenic A/H5N1 avian influenza with bronchopleural fistula. Zhonghua Jie He He Hu Xi Za Zhi 2009; 32:356-9.
28. Kong LK. Letter to the editor. Transfus Apher Sci 2003; 29:101.
29. Wong V, Dai D, Wu A, Sung J. Treatment of severe acute respiratory syndrome with convalescent plasma, author reply. Hong Kong Med J 2003; 9:310.
30. Chan KK, Lee K, Lam PK, Law K, Joynt GM, Yan W. Hong Kongs experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1). Hong Kong Med J 2010; 16:447-54.
31. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44-6.
32. Zhou XZ, Zhao M, Wang FS, et al. Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area. Zhonghua Yi Xue Za Zhi 2003; 83:1018-22.
33. OMalley J, Hartman F. Treatment of influenzal pneumonia with plasma of convalescent patients. J Am Med Assoc 1919; 72:34-7.
34. McGuire L, Redden W. Treatment of influenzal pneumonia by the use of convalescent human serum. J Am Med Assoc 1919; 72:709-13.
35. Huff-Hewitt W. Human serum in influenza. Br Med J 1919; 1:575.
36. Yu H, Gao Z, Feng Z, et al. Clinical characteristics of 26 human cases of highly pathogenic avian 36]influenza A (H5N1) virus infection in China. PLoS One 2008; 3:e2985.
37. Sang L-Y, Zhuang P, Fang F. Retrospective study on collecting convalescent donorss plasma in treatment of patients with pandemic influenza A (H1N1) virus infection. Chin J Nosocomiology 2011; 21:4684-6.
38. Gould EW. Human serum in the treatment of influenza bronchopneumonia. N Y Med J 1919; 109:666-7.
39. Holst J. Convalescent serum in treatment of influenza. Nor Mag Laegevidenskaben 1919; 80:531-61.
40. Ehrenberg L, Barkman A. Convalescent serum in the prevention and treatment of influenza. Hygiea 1919; 81:113-23.
41. Lesne E, Brodin P, Saint-Girons F. Plasma therapy in influenza. Presse Med 1919; 27:181-2.
42. Miller O, McConnell W. Report of influenza treated with serum from recovered cases. Ky Med J 1919; 17:218-9.
43. Bang O. Convalescent serum in the treatment of influenza pneumonia. Nor Mag Laegevidenskaben 1920; 81:255-61.
44. Sanborn G. The use of the serum of convalescents in the treatment of influenza pneumonia: A summary of the results in a series of one hundred and one cases. Boston Med Surg J 1920; 183:171-7.
45. Nie QH, Luo XD, Hui WL. Advances in clinical diagnosis and treatment of severe acute respiratory syndrome. World J Gastroenterol 2003; 9:1139-43.
46. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10:676-8.
47. Kahn MH. Serum treatment of postinfluenzal bronchopneumonia. J Am Med Assoc 1919; 72:102-3.
48. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52:447-56.
49. Kim S-H. Treatment of Severe Pandemic Influenza A/H1N1 Infection. Infect Chemother 2009; 41:265-71.
50. Leider JP, Brunker PA, Ness PM. Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product? Transfusion 2010; 50:1384-98.